nicotine lozenge


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to nicotine lozenge: Nicotine gum

nic·o·tine loz·enge

(nik'ŏ-tēn loz'enj)
A slow-dissolving troche developed as an aid in smoking cessation.
Mentioned in ?
References in periodicals archive ?
A total of 70% of smokers on placebo initially abstained, compared with 92% of those using a nicotine patch with a nicotine lozenge, 86% on bupropion with a lozenge, 81% on bupropion, 81% on a lozenge, and 88% on a nicotine patch.
The 2006 survey, for the first time, included a question regarding coverage for the nicotine lozenge and varenicline (Chantix).
Bupropion (Zyban) alone, or in combination with the nicotine lozenge, also did not increase cessation rates among patients with a history of anxiety disorders.
Point-prevalence abstinence at 6 weeks after the end of treatment was 47% for the group using the VLN cigarette, 37% for the nicotine lozenge group and 23% for the low nicotine cigarette group (p=.
The researchers from University of Wisconsin Center for Tobacco Research and Intervention, Madison showed that smokers using a patch and nicotine lozenge were also more likely to have quit at seven days and tended to have other more positive outcomes.
Smoking abstinence at 6 weeks after the end of treatment was 47% for the VLN cigarette group versus 32% for the nicotine lozenge group.
In commenting on the NNAL levels among subjects using Ariva[R], the authors noted, "Interestingly, total NNAL levels in subjects who used Ariva, although higher, were not significantly different from those in subjects who used the medicinal nicotine lozenge.
This is especially troubling in light of the fact that Glaxo currently has an application pending before the FDA that requests approval to sell a new pharmaceutical nicotine lozenge for smoking cessation.
You can try nicotine lozenges, which dissolve in the mouth to release a dose of nicotine to help smokers reduce withdrawal symptoms associated with quitting smoking.
The global smoking cessation and nicotine de-addiction products market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the product types (nicotine replacement therapy products - nicotine gums, nicotine inhalers, nicotine lozenges, nicotine sprays, nicotine sublingual tablets, nicotine transdermal patches; drug therapy - Chantix or champix, zyban; and e-cigarettes), and forecasts growth trends (CAGR% - 2015 to 2020).
Participants were randomly assigned to use the nicotine patch, varenicline, or the nicotine patch plus nicotine lozenges.
His outpatient medications were restarted at regular dosages but he declined nicotine replacement options of nicotine lozenges or a patch saying "it does not work for me".